What's in a name? What constitutes the clinical diagnosis of osteoporosis?
Osteoporos Int., Aug;23(8):2093-7 (2012)
Obesity is not protective against fracture in postmenopausal women: GLOW.
Am. J. Med., Nov;124(11):1043-50 (2011)
Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008.
J. Bone Miner. Res., Jan;26(1):3-11 (2011)
Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
Postgrad Med., Jan;122(1):82-90 (2010)
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
Am. J. Med., Feb;122(2 Suppl):S3-13 (2009)
Assessment of inpatient fragility fracture education and outpatient follow-up at an urban tertiary care institution.
Endocr Pract., 14(1):58-68 (2008)
Enhanced prediction of fracture risk combining vertebral fracture status and BMD.
Osteoporos Int., Jun;18(6):761-70 (2007)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
Mayo Clin. Proc., Aug;81(8):1013-22 (2006)
Patients with hip fracture: what can be improved?
Bone., Feb;38(2 Suppl 2):S8-12 (2006)
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
J. Bone Miner. Res., Sep;20(9):1514-24 (2005)
Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
J. Bone Miner. Res., Aug;19(8):1215-20 (2004)
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
Arch. Intern. Med., May;164(10):1108-12 (2004)
Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions.
Semin. Arthritis Rheum., Feb;23(4):222-5 (1994)
Extensive personal experience: Paget's disease of bone.
J. Clin. Endocrinol. Metab., Feb;80(2):335-8 (1995)
Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
Calcif. Tissue Int., May;60(5):415-8 (1997)
Osteoporosis and low bone mass in premenopausal and perimenopausal women.
Endocr Pract., 6(4):296-304 (2000)
Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures.
J. Clin. Endocrinol. Metab., Aug;88(8):3482-6 (2003)
Dichloromethylene diphosphonate action in hematologic and other malignancies.
Bone., 8 Suppl 1:S57-62 (1987)
Parathyroid function in Paget's disease of bone.
J. Bone Miner. Res., Feb;4(1):75-9 (1989)
Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Osteoporos Int., May;19(5):681-6 (2008)